Dimerix Bioscience Receives Human Ethics Committee Approval to Commence Phase II Kidney Disease Trial

29 September 2014 Melbourne, Australia –Dimerix Bioscience Limited today announced receipt of ethics committee approval under the Clinical Trial Notification scheme of the Australian Therapeutic Goods administration to commence its Phase II clinical trial of DMX200 in patients with Chronic Kidney Disease.

Recruitment of patients at the Austin Hospital is expected to commence shortly. The study will investigate the effect of DMX200 on proteinuria in patients with pre existing chronic kidney disease. The DMX200 treatment involves patients who are currently treated with irbesartan, an angiotensin receptor blocker, also taking propagermanium, an anti-inflammatory molecule which acts through the chemokine 2 receptor. The study will be completed under the supervision of Professor David Power, Director of Nephrology at the Austin Hospital, as Principal Investigator.

The therapeutic rationale for DMX200 was developed from Dimerix’s core patented technology, known as Receptor – Heteromer Identification Technology (Receptor – HIT) which can be used to elucidate receptor (or drug target) interactions. Applying this technology to receptors such as G-protein coupled receptors (GPCR’s), Dimerix is able to identify differences in signalling behaviour when receptors interact as heteromers, as expected in vivo, compared with the traditional analysis of single target receptors in isolation.

Executive Chairman, Dr James Williams said “This is an exciting step for Dimerix as we focus on establishing clinical proof of concept for the DMX200 therapy in an area of unmet clinical need. We look forward to working with Professor Power and his team at the Austin hospital.”

For more information please contact:
Dr James Williams
Executive Chairman, Dimerix Bioscience Limited
Email: [email protected]

About Dimerix:
Dimerix’s lead therapy, known as DMX200, is targeted at treating patients with chronic kidney disease. The initial focus is to provide a treatment for persistent proteinuria (abnormally high levels of protein in the urine) caused by chronic kidney disease. The intention is to target rare forms of kidney disease for which Dimerix believes it may be able to obtain regulatory approval in major jurisdictions for an “orphan drug”. Information on

Dimerix is available at its website www.dimerix.com.